Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
General24 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News21 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News24 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General20 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity